Business View Oceania | April/May 2022

25 26 BUSINESS VIEW OCEANIA VOLUME 4, ISSUE 4 BUSINESS VIEW OCEANIA VOLUME 4, ISSUE 4 The power of timely, accurate diagnosis is now here. At BioSensX Global Inc. we’re on a mission to use our Saliva Glucose Biosensor to make finger-prick blood glucose testing obsolete for people living with diabetes. Easy to use Convenient Non-invasive Pain-free For more information theiqgroupglobal.com What if there was a way to get rapid and accurate monitoring and diagnostics of medical conditions at the point-of-care, with a non-invasive and pain-free test you can do at home? The Biosensor is a small organic strip that will put the power of accurate, real-time monitoring and rapid diagnostics tests in the hands of patients and their primary health practitioners. THE IQ GROUP GLOBAL is crucial for the future of medical technology, Dr. Syrmalis concludes. “Biotech lays the foundations for so many different technologies- things that will be the way of the future. We are all about translational medicine that gives us the ability to use the underlying technology of our platforms for a range of different tests and treatments. We are in a great position to bring radical positive change to the lives of patients all over the world.” have done have all been excellent.” The iQ Group Global has a staff of approximately 200 across their science, investment, and commercialisation teams. Finding the right people for the job, Dr. Syrmalis says, has been no easy feat. “There are a number of factors to consider when we look for people to join our team. We need people with the right experience, drive to succeed, and who can come in with an understanding of why our work is so important. I’m firm in the belief that you can only have a great company if you have great people. Even if you have the best idea or the best technology, if you don’t have the team to back it up, it will fizzle away. Values that we appreciate in our staff include candidness, critical and creative thinking, independence, ambition, and above all, passion.” In addition to difficulties in finding a skilled and passionate workforce, The iQ Group Global has had to overcome challenges surrounding the education of Australia’s investment community on the potential and importance of biotech as an investment sector. Dr. Syrmalis elaborates, “Biotech has a lot of intricacies and takes a lot of time and capital to develop. To take a drug from inception through to the market could take a decade and billions of dollars of investment. So changing the mindset of our investment community here from a short to long-term focus has been difficult. We have also had to work on raising awareness for biotech in general- Australia has a long history of investment in things like minerals and energy. I think the recent effects of the pandemic have had some positive effects for medical investment, in that people are seeing the value in medical technology a lot more.” Looking to the future, The iQ Group Global aims to further develop medical innovations through The Biosensor Platform and the Tex Core Oncology Platform. Investment in biotech PREFERRED VENDORS/PARTNERS n OncoTEX Inc. oncotexinc.com OncoTEX Inc. is an oncology company developing first in class cancer therapeutics. OncoTEX manages TEX Core, a novel oncology drug platform that enables the development of well-tolerated, MRI-detectable cancer-fighting drugs that transform current cancer treatments by directly targeting tumors whilst minimizing the toxic side-effects of traditional platinum-based chemotherapy. n BioSensX Global Inc. theiqgroupglobal.com BioSensX Global Inc. is a medical technology company developing, marketing and commercialising more than 150 real-time, non-invasive diagnostic tests based on the Biosensor Platform technology, ranging from diabetes management to immunological conditions and communicable diseases, for both patients and their primary health practitioners.